Emcure Pharmaceuticals Ltd
Incorporated in 1981, Emcure Pharmaceuticals Limited is an Indian company that develops, manufactures, and markets a wide range of pharmaceutical products globally across several major therapeutic areas.[1]
- Market Cap ₹ 26,652 Cr.
- Current Price ₹ 1,409
- High / Low ₹ 1,455 / 1,225
- Stock P/E 158
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 10.7 %
- ROE 9.14 %
- Face Value ₹ 10.0
Pros
Cons
- The company has delivered a poor sales growth of 7.35% over past five years.
- Company has a low return on equity of 13.9% over last 3 years.
- Dividend payout has been low at 11.6% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 2,454 | 2,376 | 3,107 | 3,387 | 3,107 | 3,498 | |
| 1,883 | 1,948 | 2,367 | 2,593 | 2,668 | 3,056 | |
| Operating Profit | 570 | 428 | 740 | 795 | 439 | 442 |
| OPM % | 23% | 18% | 24% | 23% | 14% | 13% |
| 56 | 89 | 90 | 133 | 119 | 129 | |
| Interest | 127 | 137 | 118 | 145 | 167 | 166 |
| Depreciation | 130 | 155 | 154 | 166 | 179 | 205 |
| Profit before tax | 370 | 225 | 558 | 616 | 212 | 200 |
| Tax % | 23% | 22% | 25% | 28% | 25% | 20% |
| 284 | 175 | 420 | 447 | 160 | 161 | |
| EPS in Rs | 15.68 | 9.69 | 23.25 | 24.71 | 8.85 | 8.88 |
| Dividend Payout % | 16% | 0% | 4% | 12% | 23% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 4% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -12% |
| 3 Years: | -26% |
| TTM: | 2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 14% |
| Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 181 | 181 | 181 | 181 | 181 | |
| Reserves | 1,597 | 1,734 | 2,121 | 1,532 | 1,661 | |
| 1,224 | 1,243 | 1,603 | 1,579 | 1,668 | ||
| 576 | 713 | 958 | 1,032 | 1,106 | ||
| Total Liabilities | 3,578 | 3,871 | 4,863 | 4,323 | 4,616 | |
| 1,100 | 1,166 | 1,147 | 1,151 | 1,268 | ||
| CWIP | 406 | 326 | 192 | 239 | 253 | |
| Investments | 311 | 408 | 864 | 563 | 690 | |
| 1,761 | 1,971 | 2,660 | 2,369 | 2,405 | ||
| Total Assets | 3,578 | 3,871 | 4,863 | 4,323 | 4,616 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 371 | 385 | 775 | 428 | 505 | ||
| -276 | -169 | -836 | -394 | -271 | ||
| -53 | -46 | 31 | -343 | -55 | ||
| Net Cash Flow | 42 | 170 | -30 | -309 | 180 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 135 | 175 | 117 | 109 | 124 | |
| Inventory Days | 243 | 200 | 183 | 202 | 214 | |
| Days Payable | 159 | 197 | 169 | 166 | 203 | |
| Cash Conversion Cycle | 220 | 177 | 131 | 144 | 135 | |
| Working Capital Days | 131 | 146 | 97 | 132 | 128 | |
| ROCE % | 13% | 19% | 21% | 11% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
19 Aug - Dated August 8, 2024, please find enclosed the transcript of the Earnings Call for the Q1 FY25, held on Wednesday, August 14, 2024 at 8.30 …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Aug - Extracts of the Unaudited Financial Results of the Company for the quarter ended June 30, 2024, as published in the newspapers viz. "Financial Express" and …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
14 Aug - Dated August 8, 2024, regarding earnings call, the audio recording of the call held today is available on our website.
- Board Meeting Outcome for Outcome Of Board Meeting Held On August 13, 2024 13 Aug
- Outcome Of Board Meeting Held On August 13, 2024 13 Aug
Concalls
-
Aug 2024TranscriptPPT
Market Leadership[1] Emcure was ranked 13th in domestic sales and ranked fourth in its covered markets for FY24. It was the largest pharmaceutical company in the gynecology and HIV antivirals therapeutic areas in terms of domestic sales for MAT FY2024.